Inflammation in Chronic HIV Infection: What Can We Do?

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 339-342

  Erlandson, Kristine M ^a   Campbell, Thomas B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; CD38 ANTIGEN; CD8 ANTIGEN; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HLA DR ANTIGEN; INTERLEUKIN 6; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; VALGANCICLOVIR; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; INTEGRASE INHIBITOR;

ANEMIA; ANTIGEN EXPRESSION; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CHRONIC DRUG ADMINISTRATION; CHRONIC INFLAMMATION; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG USE; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFLAMMATION; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MIXED INFECTION; MORTALITY; MULTIPLE CYCLE TREATMENT; NOTE; OBESITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHYSICAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEDENTARY LIFESTYLE; SMOKING; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION; FEMALE; HIV INFECTIONS; IMMUNOLOGY; MALE; MONOCYTE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIGENS, CD14; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MONOCYTES;

EID: 84939508169     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv007     Document Type: Note

References (51)

1. De Pablo-Bernal RS, Ruiz-Mateos E, Rosado I, et al. TNF-alpha levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. J Antimicrob Chemother 2014; 69:3041-6.
2. McKibben RA, Margolick JB, Grinspoon S, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015; 211:1219-28.
3. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-36.
4. Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
5. Hileman CO, Labbato DE, Storer NJ, Tangpricha V, McComsey GA. Is bone loss linked to chronic inflammation in antiretroviralnaiveHIV-infected adults? A 48-week matched cohort study. AIDS 2014; 28:1759-67.
6. Borges AH,Weitz JI, Collins G, et al. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS 2014; 28: 1791-6.
7. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis 2013; 208:249-59.
8. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: Analysis of the FRAM study cohort. J Acquir Immun Def Syndr 2010; 55:316-22.
9. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDSdefining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
10. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2014; doi:10.1097/QAD.0000000000000545.
11. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-36.
12. Peters L, Neuhaus J, Duprez D, et al. Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. J Clin Virol 2014; 60:295-300.
13. Masia M, Robledano C, Ortiz de la Tabla V, et al. Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. PLoS One 2014; 9:e105442.
14. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol 2010; 172:363-71.
15. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
16. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21:6-13.
17. Valiathan R, Miguez MJ, Patel B, Arheart KL, Asthana D. Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: A cross-sectional pilot study. PLoS One 2014; 9:e97698.
18. Salter ML, Lau B, Mehta SH, Go VF, Leng S, Kirk GD. Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections. J Acquir Immun Def Syndr 2013; 64:488-95.
19. Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC. C-reactive protein and depression in persons with human immunodeficiency virus infection: The Positive Living with HIV (POLH) study. Brain Behav Immun 2014; 42:89-95.
20. Koethe JR, Dee K, Bian A, et al. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29:1019-25.
21. Betene ADC, De Wit S, Neuhaus J, et al. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy. J Acquir Immun Def Syndr 2014; 67:538-46.
22. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203:1474-83.
23. Yi TJ,Walmsley S, Szadkowski L, et al. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis 2013; 57:1331-8.
24. Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 2014; 210:1549-54.
25. Tenorio AR, Chan ES, Bosch RJ, et al. Rifaximin has amarginal impact onmicrobial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy-ACTG A5286. J Infect Dis 2015; 211:780-90.
26. Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: A double-blind, randomized, placebo-controlled trial. J Acquir Immun Def Syndr 2014. Epub ahead of print.
27. Fabre-Mersseman V, Tubiana R, Papagno L, et al. Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. AIDS 2014; 28:2677-82.
28. Metkus TS, Timpone J, Leaf D, Bidwell Goetz M, Harris WS, Brown TT. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med 2013; 14:530-9.
29. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209:1156-64.
30. Calza L, Vanino E, Salvadori C, et al. Tenofovir/ emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials 2014; 15:1-13.
31. Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrin Metab 2008; 93:3860-9.
32. Wooten JS, Nambi P, Gillard BK, et al. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc 2013; 45:1043-50.
33. Longo V, Bonato M, Bossolasco S, et al. Brisk walking improves inflammatory markers in cART-treated patients. In: Program and abstracts of the Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2014.
34. HIV treatment: FDA-approved HIV medications. Updated 10 December 2014. http:// aidsinfo.nih.gov/education-materials/factsheets/ 21/58/fda-approved-hiv-medicines. Accessed 23 December 2014.
35. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26:1371-85.
36. Papakonstantinou VD, Chini M, Mangafas N, et al. In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients. Lipids Health Dis 2014; 13:90.
37. Hileman CO, Wohl DA, Tisch DJ, Debanne SMMcComsey GA. Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to nonabacavir-containing regimens. AIDS Res Hum Retroviruses 2012; 28:1561-4.
38. Silva EF, Charreau I, Gourmel B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013; 208:892-7.
39. Lake JE, McComsey GA, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: TheWomen, Integrase and Fat Accumulation Trial. HIV Med 2014; 15:431-41.
40. Gupta SK, Mi D, Moe SM, Dube MP, Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: A randomized, controlled trial. J Acquir Immun Def Syndr 2013; 64:279-83.
41. Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013; 27:1413-9.
42. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-60.
43. Hatano H, Strain MC, Scherzer R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: A randomized, placebo-controlled trial. J Infect Dis 2013; 208:1436-42.
44. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIVinfected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-8.
45. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 2010; 7.
46. Chege D, Kovacs C, la Porte C, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: A randomized controlled trial. AIDS 2012; 26:167-74.
47. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-5.
48. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, MD: AIDSinfo, Department of Health and Human Services, 2014. http://aidsinfo.nih.gov/guidelines. Accessed 15 December 2014.
49. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312:1006-15.
50. Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. Shock 1997; 7:170-4.
51. Opal S, Laterre PF, Abraham E, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32: 332-41.